Norris Medicines Ltd

Norris Medicines Ltd (NORRIS) is a micro-cap Commercial Services company valued at ₹16 crore operating in Trading & Distributors on the NSE and BSE.

Recent price move

Norris Medicines Ltd last traded at ₹16, up 4.37% on the day.

Recent developments

On 2026-06-30, the company reported a net loss of ₹0 crore for the latest financial year, matching the prior year's loss. In the latest quarter, revenue dropped 37.0% to ₹1 crore, though net profit stayed at a loss. The company's net profit margin improved significantly, rising 17.8 percentage points to -3.5%.

Financial performance

The company's business improved with annual revenue rising 39.7% to ₹8 crore, but net profit remained at a loss. The latest quarter saw revenue fall 37.0% year-on-year to ₹1 crore, while the net profit loss remained unchanged.

Valuation multiples

A price-to-earnings ratio is not meaningful here because the company is loss-making; the stock trades at -0.96 times book value.

Things to watch

The company continues to report a net loss, despite a narrowing margin. Revenue growth has been negative over the past five years, declining at -7.9% annually. The stock is 23.6% below its 52-week high, and the latest quarter's revenue fell sharply compared to the same period a year earlier.

Where it stands

Norris Medicines Ltd ended the latest financial year with a net loss of ₹0 crore, though the margin improved. Revenue growth has been weak over the past five years, and the latest quarter saw a sharp drop in revenue. The stock is trading 23.6% below its 52-week high.

Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.